Business
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program
InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Ca...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate - INM-755 - for its Epidermolysis Bullosa Program\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 13, 2019\n\n\n\nTransition to INM-755 Expected to Improve the Probability of Development and Regulatory Success\nInitiation of a Phase I Clinical Trial Remains On-track\nTSX:INOTCQX:IMLFF\n VANCOUVER, March 13, 2019 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis platform technology for the manufacturing of pharmaceutical-grade cannabinoids as well as a R&D pipeline of medications targeting diseases with high unmet medical needs, today provided an update on its drug development program for the treatment of Epidermolysis Bullosa (\"EB\").\n\n \n \n\n \nThe Company has determined that the clinical development path forward with its investigational drug candidate for the treatment of EB, previously referred to as INM-750, will be optimized by transitioning to an alternative formulation, now designated as INM-755. INM-755 is formulated based on one of the two cannabinoids that comprised INM-750.\nAlexandra D.J. Mancini, MSc, InMed's Senior Vice President, Clinical and Regulatory Affairs, commented, \"Our decision to move forward in clinical development with INM-755 is data-driven.  Moreover, we believe that pursuing a single-agent formulation, rather than a combination product, will ultimately improve the probability of development and regulatory success in this complex and rare disease.\" Ms. Mancini continued, \"INM-755 will be developed based on its potential to provide symptomatic benefit for all EB patients, and possibly improve skin integrity in a subset of EB Simplex patients through keratin up-regulation.\"\nThe Company remains on track to file a Clinical Trial Application with Health Canada in the second half of 2019, with the initiation of a Phase I clinical trial begin...